Mankind Pharma liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

7.34×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.10×	1.10×	1.27×	3.14×	2.38×
0.77×	0.77×	0.90×	2.40×	1.57×
2,547	1,929	2,098	2,640	1,380
2,184	632	1,512	4,528	2,564

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,469.30

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.02L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	7.34
Current Ratio	2.38	3.14	1.27	1.10	1.10
Quick Ratio	1.57	2.40	0.90	0.77	0.77
Cash, Equiv & ST Investments	1,380.3	2,640.1	2,098.2	1,929.0	2,546.6
Working Capital	2,563.9	4,527.8	1,511.5	632.4	2,184.1

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.